Shares of Black Diamond Therapeutics, Inc. (BDTX) jumped around 21% as of Wednesday noon after the company announced it had ...
H.C. Wainwright raised the firm’s price target on Black Diamond Therapeutics (BDTX) to $12 from $11 and keeps a Buy rating on the shares ...
Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...